Clinical Trial

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2024-10-30; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2025-03-27
Trial Details
NCT Number NCT06668181
Lead Sponsor UCB Biopharma SRL
Conditions Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
Enrollment 40 participants
Start Date 2025-03-11
Primary Completion 2028-04-12 (estimated)
Study Completion 2030-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-17